Can Focinvez prevent chemotherapy-induced nausea and vomiting in cancer patients?
Focinvez (fosaprepitant) is a prescription medicine approved by the FDA to help prevent nausea and vomiting caused by chemotherapy. It works by blocking a substance in the brain called substance P/neurokinin-1 (NK1). Focinvez is not used alone; it is given together with other antiemetic medications. It is meant to prevent CINV, not to treat it once it has started.
What the research says
The FDA has approved Focinvez for preventing both acute and delayed nausea and vomiting from highly emetogenic chemotherapy (like high-dose cisplatin) and for delayed nausea and vomiting from moderately emetogenic chemotherapy 5. This approval is based on clinical studies showing that adding an NK1 receptor antagonist like fosaprepitant to standard antiemetic therapy improves control of CINV, especially in the delayed phase 5. Guidelines from major cancer organizations (ASCO, NCCN, MASCC/ESMO) recommend using a combination of antiemetics, including NK1 antagonists, for patients receiving highly emetogenic chemotherapy 6. Other antiemetics, such as ondansetron (a 5-HT3 antagonist), are also FDA-approved for CINV prevention 3. A network meta-analysis found that palonosetron (a newer 5-HT3 antagonist) is more effective than ondansetron for delayed vomiting, and adding dexamethasone further improves outcomes 4. Non-drug approaches like acupuncture or electronic acupoint stimulation may also help, but the evidence is less certain 27.
What to ask your doctor
- Is Focinvez right for my chemotherapy regimen?
- What other antiemetics should I take with Focinvez?
- When and how will I receive Focinvez (IV infusion)?
- What are the possible side effects of Focinvez?
- Are there any non-drug options I can try to help with nausea and vomiting?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.